Onward Therapeutics Announces Enrollment of Phase 1 Clinical

Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

Related Keywords

Epalinges , Switzerland General , Switzerland , France , Paris , France General , Taipei , T Ai Pei , Taiwan , Alain Herrera , Biomunex Pharmaceuticals , Onward Therapeutics , Chief Medical , Bispecific Antibody , Hematological Malignancies , Phase 1 Clinical Trial , Herapeutics , Development , Immune Checkpoints , Iopharmaceutical Company , Drug Development , Solid Tumors , Cancer Treatment ,